Clinical Trials ArenaOriginal article
Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli
positiveSNIPR001Positive
AI Analysis
Summary
CRISPR Therapeutics' investigational therapy SNIPR001 was successfully administered to a patient with drug-resistant E. Coli infection under a single-patient emergency IND.
Clinical Trial Data
Primary Endpoint
Met
Patients
1
Outcome Details
CRISPR therapy SNIPR001 administered successfully to patient with drug-resistant E. Coli under emergency IND
Importance:4/10
Sentiment:
0.70
CRISPRgene-editinginfectious-diseaseemergency-INDsingle-patient
Related Companies
Read the original article
Published by Clinical Trials Arena on August 12, 2026 10:19 AM